FDA sunscreen rule
This article was originally published in The Rose Sheet
Executive Summary
FDA is extending the comment period for its proposed sunscreen regulation to Dec. 26, 2007; the 90-day comment period initially was set to end Nov. 26. The proposed rule will amend the 1999 FDA final rule on sunscreens that block UVB rays to incorporate new testing and labeling requirements for products that protect against UVA rays (1"The Rose Sheet" Aug. 27, 2007, p. 3). The extension is in response to nine requests submitted to extend the comment period; eight of the requests were for an additional nine months in order to conduct laboratory testing and consumer studies on the proposed labeling system. "By extending the comment period for 30 days, FDA is balancing industry concerns and the interests of public health to ensure that sunscreen products properly inform customers of the level of protection they provide against UVA and UVB rays," the agency says Nov. 27...
You may also be interested in...
Sunscreen Proposed Rule May Create UVA Protection Marketing Opportunity
FDA's proposed rule amending its final monograph on sunscreens to include UVA ray protection standards could create new marketing opportunities for manufacturers
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.